Tamara Fountain
Known title: DirectorCIK: 0001902243
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Sight Sciences to Show OMNI Ultra System at 2026 AOO Meeting. Sight Sciences plans to debut its new OMNI Ultra Surgical System at the upcoming American Academy of Ophthalmology Annual Meeting. This event highlights the company's continued focus on advancing ab interno canaloplasty technology. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 28,261 | $0 | 6/4/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 30,952 | $0 | 6/5/2025 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| RXST | ▼ Sell | Open Market | 7,000 | $180K | 3/12/2025 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| SGHT | ▲ Buy | Grant | 17,366 | $0 | 6/6/2024 | View on chart |
| SGHT | ▲ Buy | Grant | 15,094 | $0 | 6/8/2023 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| RXST | ▲ Buy | Grant | 19,196 | $0 | 1/19/2023 | View on chart |
| RXST | ▲ Buy | Grant | 4,312 | $0 | 1/19/2023 | View on chart |
| SGHT | ▲ Buy | Grant | 17,977 | $0 | 1/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.